The American Life Sciences Innovation Council (ALSIC) is a social welfare organization created in 2010 to support policies that foster an environment in which medical innovation can thrive. Our mission is to educate the public and policymakers about the effects of government regulation on key factors that drive life science innovation.
Key Factors Driving Life Science Innovation
- Strong intellectual property protection
- Adequate reimbursement driven by market forces
- Unfettered collaboration with basic science partners
- A transparent and predictable regulatory environment
- Access to capital
What We Do
ALSIC engages thought leaders, trade and professional associations, policymakers, and the general public through long-term advocacy campaigns to bring attention to policies that will promote innovation in the life sciences. Additionally, ALSIC communicates its message on the issues surrounding life science innovation to the public through all forms of mass communication—including, but not limited to, print advertising, cable television and radio messaging, as well as e-mail and direct-mail communications.
ALSIC shares its research and policy positions with policymakers and encourage its supporters and the general public to communicate their views on these issues at all levels of government. ALSIC seeks the commitment of these policymakers to implement statutes, rules, and regulations consistent with principles supporting life science innovation.
Board of Directors
Mr. Harrison is a regulatory and quality assurance expert in drug development, and is the President and Chief Executive Officer of VIDA Sciences. He formerly held positions of increasing responsibility, including President and Chief Operating Officer, at MPI Research, a large contract research organization that provides extensive preclinical management services. Mr. Harrison has also served as the President of the Society of Quality Assurance.
H. Dean Hart
Mr. Hart is an accomplished executive in the life sciences arena with decades of commercial experience including directing national sales and marketing for several leading pharmaceutical manufacturers. He presently serves as the Chief Commercial Officer of NanoInk, Inc., an emerging growth technology company specializing in nanometer-scale applications for the life sciences and pharmaceutical industry. In this role, Mr. Hart directly oversees the company’s pharmaceutical supply chain security and brand protection division and provides strategic consulting for NanoInk’s other commercial entities.
Mr. Knuth is a 20-year veteran in the fields of alliance development and grassroots advocacy. He serves as the Chief Executive Officer at Public Affairs Company, a Minneapolis-based government relations firm with more than a decade of experience in the health care arena. Mr. Knuth’s work includes extensive experience in assisting the life sciences industry in nationwide, coordinated advocacy efforts on health policy initiatives.
Mr. Mohler is a leading public policy attorney and consultant to the life sciences industry. He has more than 15 years of experience advising biotech, pharmaceutical, medical device and other life science clients and trade associations on the federal level. Mr. Mohler’s policy and advocacy experience spans a number of areas including federal regulations and legislation affecting patients and manufacturers.
Mr. Schwartz is a trial attorney and the founder of Schwartz Law Firm. For over 40 years, he has provided counsel and litigation representation in a wide variety of legal matters and utilizes his experience to presciently guide clients through difficult issues.